Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01
January 15, 2025 08:00 ET
|
Evaxion Biotech
Trial remains on track for completion and data readout in the second half of 2025 COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio...